Table 7. Logistic regression model of factors associated with exposure to each criteria of PP, PIM and DDI.
| Polypharmacy | PIM | DDI | |
|---|---|---|---|
| Variables | Adjusted OR (95%CI)a | Adjusted OR (95%CI)a | Adjusted OR (95%CI)aS |
| Patient characteristics | |||
| Number of comorbidities | 1.24 (1.03–1.48)* | ||
| History of GERD | 6.03 (1.64–22.09)** | ||
| Medications characteristics | |||
| Number of medications | -b | 1.46 (1.17–1.82)** | |
| A06 Drugs for constipation | 14.21 (4.16–48.60) ** | ||
| A11 Vitamins | 3.73 (1.25–11.17)* | ||
| A12 Mineral supplements | 10.82 (2.29–51.09) ** | ||
| B01 Antithrombotic agents | 5.15 (1.63–16.28) ** | ||
| C01 Cardiac therapy | 3.47 (1.80–6.66)** | ||
| C02 Antihypertensives | 6.24 (1.26–30.83) * | ||
| C03 Diuretics | 120.83 (8.70–1678.36) ** | 12.72 (1.64–98.68)* | |
| C08 Calcium channel blockers | 7.48 (1.42–39.45) * | ||
| C09 Agent acting on the renin- angiotensin system | 9.81 (2.80–34.37) ** | ||
| C10 Lipid modifying agents | 14.55 (3.29–64.16) ** | ||
| J01 Antibacterial drugs | 29.29 (4.79–178.80) ** | ||
| N02 Analgesics | 10.13 (2.97–34.52) ** | ||
| N05 Psycholeptics | 19.71 (4.88–79.64) ** | 18.38 (9.73–34.73) ** | |
| N06 Psychoanaleptics | 2.26 (1.30–3.93) ** | 6.14 (2.35–16.08)** | |
| Presence of PP | -b | 3.04 (1.12–8.27)* | |
| Presence of PIM | 0.30 (0.09–1.01) | -b | 2.07 (1.07–4.00)* |
| Presence of DDI | 34.16 (9.59–121.69) ** | 1.97 (1.08–3.62)* | -b |
a Adjusted for age, sex, number of comorbidities, short ADL scale, premorbid IADLs and significant variable from unadjusted model
* P<0.05
**P<0.01
-b Not include in adjusted analyses.
Data are presented as odds ratio (95% confidence interval).
Abbreviations: GERD, gastroesophageal reflux disease; PP, polypharmacy; PIM, potentially inappropriate medication; DDI, drug-drug interaction; OR, odds ratio; CI, confidence interval.